DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Graig Suvannavejh - 3 Eli Lilly - 2 Lilly - 2 it's - 2 Goldman Sachs - 2 Chris Shibutani - 2 Jonathan Wolleben - 2 Wolleben - 2
Top related locs:
Keytruda Novo GLP Eventide Danish Shandong Fujian Viking
Top related orgs:
EyePoint Pharmaceuticals - 2 Novo Nordisk - 2 Pfizer - 2 Novo - 2 Therapeutics - 2 Mizuho Securities - 2 Universal Health Services - 1 Block - 1

Search resuls for: "Graig Suvannavejh"


5 mentions found


☆ These are Mizuho’s top stock picks heading into May
  + stars: | 2024-05-03 | by ( Lisa Kailai Han | ) www.cnbc.com   time to read: +2 min
Mizuho just released its top stock picks for May, and its basket of stocks includes three new selections for the month. The newest additions for May include EyePoint Pharmaceuticals , Universal Health Services and Block . Here are some of Mizuho's top picks for the month. Mizuho said this price target is 5.3% above the consensus, making the firm more bullish than its peers. Analyst Graig Suvannavejh's $39 price target represents 95% upside from where shares closed on Thursday.
Persons: Mizuho, Ann Hynes, Hynes, UHS, Graig, EyePoint, Dan Dolev's, Dolev Organizations: EyePoint Pharmaceuticals, Universal Health Services, Block, titans, Microsoft, Behavioral
☆ These are Mizuho's top stock picks heading into November
  + stars: | 2023-11-05 | by ( Alex Harring | ) www.cnbc.com   time to read: +3 min
Mizuho's equity research team compiled its top buy-rated picks for the new month. The average price target for the stock, which is already up about 14% this year, implies an upside of about 15%. But the average analyst is bullish with a buy rating and price target implying an upside of almost 21%, per LSEG. The average Wall Street analyst rates EyePoint a buy, and the consensus price target implies the stock could skyrocket nearly 290%, per LSEG. The average analyst has a buy rating and price target reflecting 13.5% upside ahead, per LSEG.
Persons: Nitin Kumar, Mara Goldstein, Graig Suvannavejh, Siti Panigrahi, INTU, Panigrahi, — CNBC's Michael Bloom Organizations: Mizuho, Dow Jones, Nasdaq, Coterra Energy, Merck, Co, EyePoint Pharmaceuticals, Intuit, Small Locations: Keytruda
☆ Here are 5 anti-obesity drug stocks besides Novo Nordisk and Eli Lilly to watch into year-end
  + stars: | 2023-10-29 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +11 min
Novo Nordisk and Eli Lilly reign over the anti-obesity drug market, and don't expect this duopoly to end soon, analysts say. All this goes on amid robust demand for Novo's semaglutide, which is sold as Ozempic for type 2 diabetes and as Wegovy for weight loss, and Lilly's tirzepatide, which hopes to receive regulatory approval for weight loss this year. Orforglipron is an oral drug Eli Lilly is developing. It has several other compounds in the pipeline, but Suvannavejh expects the weight loss drug to receive increased attention. "This range would also be competitive with LLY's orforglipron [an oral GLP-1 drug] weight loss at day 28," Smith said.
Persons: Eli Lilly, Piper Sandler, Yasmeen Rahimi, Cantor Fitzgerald, Louise Chen, Lilly, Lilly's, Chen, Price, Kyle Rasbach, We've, Rasbach, Altimmune Altimmune, NASH, Piper's, Rahimi, Cantor's Chen, it's, Eli Lilly's Mounjaro, Goldman Sachs, Chris Shibutani, David Risinger, Risinger, Jonathan Wolleben, Wolleben, Orforglipron, Graig Suvannavejh, Suvannavejh, Thomas Smith, LLY's, Smith, Yale Jen, Jen Organizations: Novo Nordisk, Pfizer, Novo, pharma, Pfizer Pfizer, danuglipron, Therapeutics, Leerink, Mizuho Securities, Viking Therapeutics Viking Therapeutics, Laidlaw & Co Locations: Novo, GLP, Eventide
☆ The options for weight loss treatment are about to explode. These are the companies investors need to know
  + stars: | 2023-07-03 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +14 min
Wegovy was approved as an obesity treatment in June 2021 , but Ozempic, a Type 2 diabetes treatment, has been used off-label for weight loss. Mounjaro uses GLP-1 and gastric inhibitory polypeptide, or GIP, to help patients lose weight. Eli Lilly's oral drug, orforglipron, has an even better profile . They also could be helpful in assisting patients in maintaining weight loss after they've used the injectable versions, he said. Some have highlighted that oral drugs also may be more manageable for patients who can't handle the idea of giving themselves a once-a-week injection.
Persons: Eli Lilly, we're, Jonathan Wolleben, Wegovy, Lilly's tirzepatide, It's, Mounjaro, Wolleben, Eli Lilly's tirzepatide, Lilly, —, Novo, Eli, it's, they've, FactSet, Altimmune's pemvidutide, Morgan Stanley, Mark Purcell, Purcell, Graig Suvannavejh, Suvannavejh, Roth, Dylan Dupuis, Dupuis, Trung Huynh, Goldman Sachs, Chris Shibutani, Shibutani Organizations: Novo Nordisk, JMP Securities, Citizens Company, Nordisk's Ozempic, Food and Drug Administration, Nordisk, Novo, Zealand Pharma, Shandong Suncadia, GSBR, Biosciences, Fujian Shengdi Pharmaceutical, Mizuho Securities, Terns Pharmaceuticals, American Diabetes Association, Viking Therapeutics, Pfizer, Credit Suisse, AstraZeneca, Therapeutics, Medicare, Medicaid, CNBC Pro's Locations: Danish, Shandong, Fujian, Viking
☆ The success of Biogen's new Alzheimer's drug could be the start of a redemption arc for the biotech — and boost rivals racing to develop similar treatments
  + stars: | 2022-09-28 | by ( Yeji Jesse Lee | ) www.businessinsider.com   time to read: +3 min
Biotech companies Biogen and Eisai just released data on their new Alzheimer's drug. Initial results of a highly anticipated test of an Alzheimer's drug, called lecanemab, were released on Tuesday evening by biotech firms Biogen and Eisai. "While the market has been skeptical of lecanemab's prospects, the trial appears to be a resounding success," Cowen analysts said. An earlier Alzheimer's drug developed by Biogen and Eisai, Aduhelm, also acts on beta-amyloid. Mizhuo analyst Graig Suvannavejh, said that the lecanemab results are "a key potential positive catalyst for companies" working to develop Alzheimer's treatments.
0 next >>
Total: 5